DaVita Earnings Call Transcripts
Fiscal Year 2026
-
Volume guidance was raised due to competitor clinic closures and improved mortality, with most benefits expected by mid-year. OI growth is supported by international and value-based care, while AI and clinical innovations are being pursued for future efficiency and patient outcomes.
-
First quarter results exceeded expectations, driven by higher treatment volume, improved productivity, and technology investments. Guidance for adjusted operating income and EPS was raised, with additional volume growth expected from competitor clinic closures.
-
2026 OI growth is projected above the low end of long-term targets, driven by U.S. dialysis, international, and IKC segments. Margin maintenance, cost controls, and IT investments are key, while APTC expiration and clinical programs will shape future mix and volume. Double-digit EPS growth and disciplined capital deployment remain priorities.
Fiscal Year 2025
-
Fourth quarter and full-year 2025 results met expectations, with adjusted operating income of $2.094 billion and first profitable year in IKC. 2026 guidance calls for 3.2% OI growth and 33% EPS growth, supported by clinical initiatives and capital discipline.
-
Volume and revenue per treatment were challenged by flu and a cyber incident, but guidance was maintained. Mortality and mistreatment rates remain elevated, with future growth hinging on operational improvements and mortality reduction. Capital allocation is focused on share buybacks and disciplined M&A.
-
Q3 results met expectations with $517M adjusted operating income and $2.51 EPS, despite a 1.5% decline in U.S. treatment volume due to discrete events. Full-year guidance is reaffirmed, with 2026 outlook hinging on volume recovery, payer mix, and policy changes.
-
Q2 results met expectations despite cyber and volume headwinds, with strong cost control offsetting revenue and treatment declines. Full-year guidance for operating income, EPS, and free cash flow was reaffirmed, while persistent elevated mortality and mistreatment rates remain key challenges.
-
Q1 adjusted operating income and EPS exceeded expectations despite a cyber incident and flu-related headwinds. Guidance for 2025 is maintained, with phosphate binder profitability and strong international results offsetting lower treatment volumes and cyber costs.
-
Flat treatment growth is forecast for 2024, with ongoing cost pressures from labor and inflation. Regulatory changes, such as the transition of oral phosphate binders to TDAPA, and evolving ACA subsidy dynamics are key financial factors. International growth and integrated kidney care remain strategic priorities.
Fiscal Year 2024
-
2024 saw strong adjusted OI and EPS growth despite supply and weather disruptions, with continued international expansion and stable core operations. 2025 guidance projects flat treatment volume, 5.2% OI growth, and 11% EPS growth, with capital returned to shareholders and key risks from volume and reimbursement variability.
-
Revenue per treatment and labor costs have outperformed expectations, while patient volume remains below pre-COVID levels due to persistent elevated mortality. Regulatory changes, supply chain issues, and payer mix shifts are shaping the outlook, with 2025 expected to balance headwinds and tailwinds.
-
Q3 results met expectations with $535M adjusted OI and $2.59 EPS, despite hurricane and supply chain disruptions. 2024 guidance is reaffirmed, with headwinds from elevated mortality and supply issues offset by international growth and declining closure costs. RPT and patient care costs remain elevated.
-
Q2 2024 results exceeded expectations with strong RPT growth and disciplined cost management, though volume growth lagged due to weather and elevated mortality. Guidance for adjusted operating income and EPS was raised, with center closure costs now included in adjusted results.